Kairos Pharma (KAPA): Multiplikator Forward P/S

Kairos Pharma Limited (KAPA) - logo korporat

Kairos Pharma Ltd (KAPA) utilizes California-based bioengineering centers, delegating drug production to CDMO partners to minimize risks. American laboratories are creating unique molecules that overcome tumor drug resistance. High physician confidence confirms the company's status as a scientific innovator. The business's forward P/S reflects the current market valuation, where the mark records this metric.

KAPA Kairos Pharma Limited: Rega forward marang dodolan ing interval 04.07.2022 - 16.11.2026

Rincian analitis perusahaan Kairos Pharma Ltd

Ringkesan analisis perusahaan:KAPA (Kairos Pharma Ltd)
Produk asli Kairos Pharma Limited

The specific nature of the biopharmaceutical sector makes asset valuation vulnerable to market volatility; however, the use of CDMO contractors for drug production minimizes operational risks for Kairos Pharma Ltd (KAPA). By analyzing the company's forward P/S, an investor can see the ratio of current market capitalization to expected annual revenue, which allows for determining the extent of the premium paid for future sales and assessing market optimism regarding the commercialization of developments.

Pesaing langsung

Multiplikator Forward P/S ONC (BeiGene Oncology)|Multiplikator Forward P/S Halozyme Corp HALO|RVMD: Multiplikator forward rega marang pendapatan|Ascentage Pharma Group (AAPG) - Multiplikator forward rega marang pendapatan|CG Oncology Therapeutics (CGON) - Rasio rega marang prakiraan pendapatan|Prakiraan rega marang pendapatan UroGen Pharma URGN|Rasio rega marang prakiraan pendapatan Bicara Bio|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Personalis Genomics PSNL|Multiplikator Forward P/S ERAS|Rasio rega marang pendapatan sing dikarepake DCTH|Y-mAbs Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Aura Biosciences Inc (AURA)|CADL: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ARAY (Accuray Inc.)|SLS: Multiplikator Forward P/S|ACTU: Rasio rega marang pendapatan sing dikarepake|CTOR (Citius Oncology Inc.) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep tuhurabio.com HURA|Multiplikator Forward P/S TARA|FATE: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX (TScan) - Rega mangsa ngarep marang pendapatan|Champions Oncology, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake XBiotech Inc XBIT|CVM: Multiplikator Forward P/S|OSTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Radiopharm Theranostics Limited|Multiplikator Forward P/S artivabio.com|Multiplikator forward rega marang pendapatan ANL (Adlai Nortye Limited)|Veru - Kapitalisasi marang prakiraan pendapatan|Tempest Therapeutics, Inc. - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake xiliotx.com (XLO)|Renovaro - Multiplikator Forward P/S|Mural Oncology (MURA) - Multiplikator forward rega marang pendapatan|OnKure Therapeutics Inc (OKUR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan CytoMed|Rasio rega marang prakiraan pendapatan curis.com|Multiplikator forward rega marang pendapatan Apollomics, Inc. (APLM)|Multiplikator Forward P/S THAR|Advanced Biomed Corp - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Genprex GNPX|Rasio kapitalisasi marang dodolan sing dikarepake Calidi Bio (CLDI)|sunshinebiopharma.com - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep xeneticbio.com|salariuspharma.com (SLRX) - Rasio rega marang prakiraan pendapatan|Purple Biotech Ltd. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan AON|Multiplikator Forward P/S BeiGene Ltd.|Rasio rega marang prakiraan pendapatan Checkpoint Therapeutics, Inc. (CKPT)|Multiplikator forward rega marang pendapatan Elevation Oncology, Inc. ELEV|Multiplikator Forward P/S ICAD (iCAD Inc.)|IKNA - Multiplikator forward rega marang pendapatan|NTBL: Multiplikator forward rega marang pendapatan|viracta.com (VIRX) - Multiplikator forward rega marang pendapatan|MorphoSys (MOR) - Rasio rega marang prakiraan pendapatan|NAYA Biosciences Corp (NAYA) - Multiplikator Forward P/S|AAPGV (Ascentage) - Multiplikator Forward P/S